PGI2 Versus Nitroglycerine for Management of Pulmonary Hypertension After Valve Surgeries
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This study was conducted in 120 patients aged from 54-65 years scheduled for elective valve
replacement surgeries. Patients were randomly allocated to nitro glycerine or PGI2 groups.
Patients of nitro glycerine group received nebulized nitro glycerine at a rate of 2.5-5
mcg/kg/min (5 mg, 1 mg/ml) over 10 minutes by ultrasonic nebuliser. Patients of PGI2 group
received nebulized PGI2 (epoprostenol), 20000 ng/ml (20000 ng/ml in 60 ml syringe was
attached to an intravenous pump which delivers a titrating rate of 8 ml/h . The primary
outcome was mean pulmonary artery pressure. The secondary outcomes included mean arterial
blood pressure (MAP) (mmHg), PaO2/FiO2 ratio, cardiac index (CI) (l/min/m2) right ventricular
ejection fraction (RVEF), central venous pressure(CVP) , 30-day mortality rate and the
incidence of complications such as facial flushing, hypotension and re-exploration for
bleeding.